Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.20 Consensus Price Target from Analysts
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target […]
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target […]
